The effect of postoperative chemotherapy on serum lipids and prognosis in patients with advanced ovarian cancer

Recent studies have shown that chemotherapy can cause abnormal blood lipid metabolism in cancer patients. However, little is known about the association between blood lipids and chemotherapy in patients with ovarian cancer. In this study, we investigated the change in blood lipid levels in patients with advanced ovarian cancer before and after adjuvant chemotherapy and its effect on patient prognosis. Serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein (HDL) levels and clinical data from 100 patients with advanced (International Federation of Gynecology and Obstetrics, FIGO stage III/IV) ovarian cancer before and after postoperative adjuvant chemotherapy were measured and analyzed, and the correlation of LDL level with overall survival (OS) was evaluated. After chemotherapy, the TG, TC, HDL and LDL levels were significantly greater than those before chemotherapy (p < 0.01). A high LDL level in patients with advanced ovarian cancer after chemotherapy was significantly correlated with poor overall survival (OS). Patients with advanced ovarian cancer have abnormal blood lipid metabolism during adjuvant chemotherapy, and elevated LDL levels after chemotherapy are significantly correlated with a poor prognosis.

Ovarian cancer; Chemotherapy; Serum lipids; Overall survival

[1] Wu SG, Li FY, Lei J, Hua L, He ZY, Zhou J. Histological tumor type is associated with one-year cause-specific survival in women with stage III–IV epithelial ovarian cancer: a surveillance, epidemiology, and end results (SEER) database population study, 2004–2014. Medical Science Monitor. 2020; 26: e920531.

[2] Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: a Cancer Journal for Clinicians. 2019; 69: 280–304.

[3] Vasseur S, Guillaumond F. Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance. Oncogenesis. 2022; 11: 46.

[4] Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. British Journal of Cancer. 2021; 124: 663–670.

[5] Li Y, Shang C, Liang H, Zhang K, Wu Y, Guo H. Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis. Frontiers in Oncology. 2023; 13: 1052760.

[6] Dong J, Kong L, Wang S, Xia M, Zhang Y, Wu J, et al. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice. Journal of Experimental & Clinical Cancer Research. 2024; 43: 102.

[7] Wang Y, Wang Y, Chen C, Ren F, Cao R, Wang Y, et al. Serum lipid profiling analysis and potential marker discovery for ovarian cancer based on liquid chromatography—mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2021; 199: 114048.

[8] Zhang D, Xi Y, Feng Y. Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: a systematic review and meta-analysis of observational epidemiologic studies. European Journal of Cancer Prevention. 2021; 30: 161–170.

[9] Onwuka JU, Okekunle AP, Olutola OM, Akpa OM, Feng R. Lipid profile and risk of ovarian tumours: a meta-analysis. BMC Cancer. 2020; 20: 200.

[10] He T, Wang C, Tan Q, Wang Z, Li J, Chen T, et al. Adjuvant chemotherapy-associated lipid changes in breast cancer patients: a real-word retrospective analysis. Medicine. 2020; 99: e21498.

[11] Zhao J, Li G, Zhao G, Wang W, Shen Z, Yang Y, et al. Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma. Frontiers in Oncology. 2022; 12: 986367.

[12] Expert Group of Integrated Cancer Cardiology Branch of National Anti-Cancer Association. Chinese expert consensus on blood lipid management of patients with malignant tumors. Chinese Journal of Oncology. 2021; 43: 1043–1053. (In Chinese)

[13] Markowska A, Kojs Z, Twardawa D, Pietras J, Markowska J. Selected markers of ovarian cancer and their relation to targeted therapy (Review). Experimental and Therapeutic Medicine. 2024; 27: 236.

[14] Goto W, Kashiwagi S, Kamei Y, Watanabe C, Aomatsu N, Ikeda K, et al. Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study. BMC Cancer. 2022; 22: 167.

[15] Garg R, Angus E, Fincher S. Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature. Diabetic Medicine. 2009; 26: 1308–1309.

[16] Saunders RA, Fujii K, Alabanza L, Ravatn R, Kita T, Kudoh K, et al. Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan. Biochemical Pharmacology. 2010; 80: 362–369.

[17] Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. American Journal of Transplantation. 2008; 8: 1384–1392.

[18] Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, de Kam ML, de Roos A, et al. Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy. Acta Oncologica. 2014; 53: 351–360.

[19] Huang XY, Huang Y, Li P. How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment? Frontiers in Oncology. 2023; 13: 1168996.

[20] Lin F, Zheng R, Yu C, Su Y, Yan X, Qu F. Predictive role of serum cholesterol and triglycerides in cervical cancer survival. International Journal of Gynecological Cancer. 2021; 31: 171–176.

[21] Patel KK, Ksahfi K. Lipoproteins and cancer: the role of HDL-C, LDL-C, and cholesterol-lowering drugs. Biochemical Pharmacology. 2021; 196: 114654.

[22] Lin Q, Liu W, Xu S, Sun L. Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer. Archives of Gynecology and Obstetrics. 2022; 305: 683–691.

[23] Garrido MM, Marta JC, Ribeiro RM, Pinheiro LC, Guimarães JT. Serum lipids and prostate cancer. Journal of Clinical Laboratory Analysis. 2021; 35: e23705.